Mitchell & Pahl Private Wealth LLC Buys 292 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mitchell & Pahl Private Wealth LLC raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,603 shares of the medical research company’s stock after acquiring an additional 292 shares during the quarter. Mitchell & Pahl Private Wealth LLC’s holdings in Charles River Laboratories International were worth $665,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International during the 3rd quarter valued at $32,000. Versant Capital Management Inc raised its stake in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the period. Assetmark Inc. lifted its holdings in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. boosted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International in the third quarter worth about $59,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. William Blair reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a report on Tuesday, January 14th. TD Cowen boosted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Redburn Atlantic began coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Finally, UBS Group reiterated a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $163.77 on Tuesday. Charles River Laboratories International, Inc. has a one year low of $160.85 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm has a market capitalization of $8.37 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. The company’s fifty day moving average price is $189.50 and its 200-day moving average price is $198.14.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the prior year, the firm earned $2.72 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).